Rchr
J-GLOBAL ID：200901086442374155
Update date: Feb. 04, 2025
MIYAKAWA Yoshitaka
ミヤカワ ヨシタカ | MIYAKAWA Yoshitaka
Affiliation and department：
Job title：
Professor
Research field (1)：
Hematology and oncology
Research theme for competitive and other funds (4)：
- 2014 - 2015 血栓性血小板減少性紫斑病に対するリツキシマブの第II相医師主導治験
- 2013 - 2015 血栓性血小板減少性紫斑病に対するリツキシマブの第II相医師主導治験
- 2014 - 現在 血液凝固異常症等に関する研究
- 2011 - 2014 特発性血小板減少性紫斑病に対するリツキシマブの開発
Papers (86)：
-
宮川義隆. 免疫性血小板減少症とB細胞. 炎症と免疫. 2025. 33. 1. 46-51
-
Cooper N, Bussel JB, Kazmierczak M, Miyakawa Y, et al. Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open label extension. Br J Haematol. 2024. in press
-
Miyakawa Y, Sato E, Ogawa Y, Nishimura JI, Nishimi M, Kawaguchi O, Tahara S, Ymaguchi M. Long term safety profile of sutimlimab in adult Japanese patients with cold agglutinin disease. Int J Hematol. 2024
-
Imada K, Miyakawa Y, Ichikawa S, et al. Frontline use of rituximab may prevent ADAMTS13 inhibitor bloosting during caplacizumab treatment in patients with iTTP: post hoc analysis of phase 2/3 study in Japan. Thrombosis Journal. 2024. 22. 72
-
Dixon BP, Kavanagh D, Aris ADM, et al. Ravulizumab in atypical hemolytic uremic syndrome: an analysis of 2 year efficacy and safety outcome in 2 phase 3 trials. Kidney Medicine. 2024. 6. 8
ｍore...
Patents (2)：
-
ヒト血小板数調節薬のスクリーニング方法
-
ヒト造血器腫瘍の動物モデル
Books (14)：
-
抗血小板同種抗体、抗血小板自己抗体「臨床検査ガイド2025年改訂版」
文光堂 2024
-
免疫性血小板減少症を含む自己免疫疾患に対する胎児性Fc受容体阻害薬「臨床雑誌 内科 特集 今この研究が面白い!」
南江堂 2024
-
免疫性血小板減少症「臨床に直結する血栓止血学 改訂3版」
中外医学社 2024
-
血液・造血器疾患患者の看護「成人看護 血液・造血器、内分泌・代謝、脳・神経」
医学書院 2024
-
12歳男児の膝関節の痛みと腫脹(血友病A)「臨床能力を評価するリアルな内科診療の問題集」
南江堂 2023
ｍore...
Lectures and oral presentations (81)：
-
Bleed protection after giroctocogene fitelparvovec infusion in adults with moderately severe to severe hemophilia A in the phase 3 AFFINE trial.
(18th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) 2025)
-
Clinical management of factor VIII elevations above normal ranges post giroctocogene fitelparvovec in Phase 3 AFFINE study
(18TH ANNUAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR HAEMOPHILIA AND ALLIED DISORDERS 2025)
-
Improved health-related quality of life (HR-QOL) with oral bruton tyrosine kinase inhibitor (BTKi) rilzabrutinib vs placebo in adults with previoulsy treated immune thrombocytopenia (ITP): phase 3 LUNA3 multicenter study
(Annual meeting of American Society of Hematology 2024)
-
Efficacy and safety of oral bruton tyrosine kinase inhibitor (BTKi) rilzabrutinib in adults with previously treated immune thrombocytopenia (ITP): a phase 3, placebo-controlled, parallel-group, multicenter study (LUNA3)
(Annual meeting of Americal Society of Hematology 2024)
-
Intravenous efgartigimod for the treatment of primary immune thrombocytopenia in adults: a planned, phase 3, randomised, double-blindded, placebo-controlled, parallel-arm study with open label period (ADVANCE NEXT)
(Annual meeting of Amecian Socieety of Hematology 2024)
ｍore...
Works (1)：
Education (1)：
- 1991 - 1995 Keio University Graduate School, Division of Medicine
Professional career (1)：
Committee career (1)：
Awards (1)：
- 2022/03 - 埼玉医科大学 埼玉医科大学ベストティーチャー賞
Association Membership(s) (2)：
Return to Previous Page
